550 related articles for article (PubMed ID: 29236174)
1. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
2. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
4. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
5. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
7. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
8. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
9. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
[TBL] [Abstract][Full Text] [Related]
10. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
[TBL] [Abstract][Full Text] [Related]
11. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
[TBL] [Abstract][Full Text] [Related]
12. Results of PONDx, a prospective multicenter study of the Oncotype DX
Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
[TBL] [Abstract][Full Text] [Related]
13. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
[TBL] [Abstract][Full Text] [Related]
15. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
16. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases.
Eichler C; Fromme J; Thangarajah F; Puppe J; Paepke S; Warm M; Malter W
Anticancer Res; 2019 Jan; 39(1):297-303. PubMed ID: 30591472
[TBL] [Abstract][Full Text] [Related]
18. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
19. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
20. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
